Abstract
Introduction: Interstitial cystitis (IC) or bladder pain syndrome (BPS) is defined as supra-pubic pain related to bladder filling. IC is characterized by a particular symptom complex with no identifiable causes; as with bladder hypersensitivity it is usually associated with urinary frequency and urgency with bladder pain. No current treatments have a significant impact on symptoms over time. Areas covered: This systematic review examines the pharmacokinetic aspects and adverse event of present IC therapy to highlight appropriate treatment to improve the symptoms of IC. This article reviews material obtained via Medline, PubMed, and EMBASE literature searches up to October 2013. Expert opinion: The correct approach to IC should consider a multidisciplinary team of specialists and a multimodal treatment package that include psychotherapy, behavior change, physical activation, and analgesic treatment. Unfortunately, a single therapeutic target for IC is not yet known. With regard to pathophysiology and therapy, there is more to discover. The first insult damages the bladder urothelium, hence vehicles that lead the drug to penetrate the wall of the bladder might be a novel strategic approach.
| Original language | English |
|---|---|
| Pages (from-to) | 673-684 |
| Number of pages | 12 |
| Journal | Expert Opinion on Drug Metabolism and Toxicology |
| Volume | 10 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Biofilms
- Bladder pain syndrome
- Interstitial cystitis
- Intravesical liposomes
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Medicine(all)
Cite this
Pharmacokinetic considerations for therapies used to treat interstitial cystitis. / Gardella, Barbara; Porru, Daniele; Allegri, Massimo; Bogliolo, Stefano; Iacobone, Anna Daniela; Minella, Cristina; Nappi, Rossella Elena; Ferrero, Simone; Spinillo, Arsenio.
In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, No. 5, 2014, p. 673-684.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacokinetic considerations for therapies used to treat interstitial cystitis
AU - Gardella, Barbara
AU - Porru, Daniele
AU - Allegri, Massimo
AU - Bogliolo, Stefano
AU - Iacobone, Anna Daniela
AU - Minella, Cristina
AU - Nappi, Rossella Elena
AU - Ferrero, Simone
AU - Spinillo, Arsenio
PY - 2014
Y1 - 2014
N2 - Introduction: Interstitial cystitis (IC) or bladder pain syndrome (BPS) is defined as supra-pubic pain related to bladder filling. IC is characterized by a particular symptom complex with no identifiable causes; as with bladder hypersensitivity it is usually associated with urinary frequency and urgency with bladder pain. No current treatments have a significant impact on symptoms over time. Areas covered: This systematic review examines the pharmacokinetic aspects and adverse event of present IC therapy to highlight appropriate treatment to improve the symptoms of IC. This article reviews material obtained via Medline, PubMed, and EMBASE literature searches up to October 2013. Expert opinion: The correct approach to IC should consider a multidisciplinary team of specialists and a multimodal treatment package that include psychotherapy, behavior change, physical activation, and analgesic treatment. Unfortunately, a single therapeutic target for IC is not yet known. With regard to pathophysiology and therapy, there is more to discover. The first insult damages the bladder urothelium, hence vehicles that lead the drug to penetrate the wall of the bladder might be a novel strategic approach.
AB - Introduction: Interstitial cystitis (IC) or bladder pain syndrome (BPS) is defined as supra-pubic pain related to bladder filling. IC is characterized by a particular symptom complex with no identifiable causes; as with bladder hypersensitivity it is usually associated with urinary frequency and urgency with bladder pain. No current treatments have a significant impact on symptoms over time. Areas covered: This systematic review examines the pharmacokinetic aspects and adverse event of present IC therapy to highlight appropriate treatment to improve the symptoms of IC. This article reviews material obtained via Medline, PubMed, and EMBASE literature searches up to October 2013. Expert opinion: The correct approach to IC should consider a multidisciplinary team of specialists and a multimodal treatment package that include psychotherapy, behavior change, physical activation, and analgesic treatment. Unfortunately, a single therapeutic target for IC is not yet known. With regard to pathophysiology and therapy, there is more to discover. The first insult damages the bladder urothelium, hence vehicles that lead the drug to penetrate the wall of the bladder might be a novel strategic approach.
KW - Biofilms
KW - Bladder pain syndrome
KW - Interstitial cystitis
KW - Intravesical liposomes
UR - http://www.scopus.com/inward/record.url?scp=84898448328&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898448328&partnerID=8YFLogxK
U2 - 10.1517/17425255.2014.896338
DO - 10.1517/17425255.2014.896338
M3 - Article
VL - 10
SP - 673
EP - 684
JO - Expert Opinion on Drug Metabolism and Toxicology
JF - Expert Opinion on Drug Metabolism and Toxicology
SN - 1742-5255
IS - 5
ER -